BT Shunt (Blalock-Taussig Shunt) — Cost, Top Hospitals & Success Rates | MyMedicPlus

The Blalock-Taussig (BT) shunt is a palliative cardiac surgical procedure that creates an artificial connection between the systemic arterial circulation and the pulmonary arteries to increase blood flow to the lungs. First performed in 1944 by Dr. Alfred Blalock and conceived by pediatric cardiologist Dr. Helen Taussig at Johns Hopkins Hospital, this groundbreaking operation was the first successful surgical treatment for cyanotic congenital heart disease and is considered one of the most important milestones in the history of cardiac surgery.

Congenital heart defects affect approximately 1 in 100 live births worldwide, with an estimated 1.35 million neonates born with congenital heart disease annually. Among these, cyanotic defects — conditions where reduced pulmonary blood flow leads to dangerously low blood oxygen levels — account for approximately 25% of all congenital heart disease. Many of these infants require surgical intervention within the first days or weeks of life to survive, and the BT shunt remains a critical component of the surgical management pathway.

The modern modified Blalock-Taussig shunt (mBTS) uses a small synthetic polytetrafluoroethylene (PTFE/Gore-Tex) tube graft, typically 3.0 to 4.0 mm in diameter, to connect the innominate or subclavian artery to the ipsilateral pulmonary artery. This provides a controlled, predictable source of pulmonary blood flow while the child grows large enough for definitive repair. The modified technique has largely replaced the original classic BT shunt due to superior flow control, preservation of the subclavian artery, and more predictable outcomes. At experienced pediatric cardiac centers, operative survival exceeds 90%.

The BT shunt is used to palliate a range of cyanotic congenital heart defects characterized by inadequate pulmonary blood flow. These conditions result in severe oxygen desaturation that, without intervention, can lead to organ damage and death in the neonatal period.

• Tetralogy of Fallot (TOF) — the most common cyanotic heart defect, featuring right ventricular outflow tract obstruction with reduced pulmonary blood flow; BT shunt used when complete repair is deferred in small or complex neonates
• Pulmonary atresia — complete absence of a functional pulmonary valve, preventing any forward flow from the right ventricle to the lungs
• Tricuspid atresia — absence of the tricuspid valve with resultant single ventricle physiology and duct-dependent pulmonary blood flow
• Hypoplastic left heart syndrome (HLHS) — BT shunt used as part of the Norwood procedure (stage I palliation) to provide pulmonary blood flow
• Transposition of the great arteries with VSD and pulmonary stenosis — reduced pulmonary flow requiring shunt augmentation
• Double outlet right ventricle (DORV) — with pulmonary stenosis causing cyanosis
• Ebstein anomaly with severe cyanosis — when right ventricular function is severely compromised
• Complex single ventricle defects — as the first stage of a staged single ventricle palliation pathway leading to eventual Fontan completion

Candidates for a BT shunt are primarily neonates and young infants with cyanotic congenital heart defects who are too small, too sick, or have anatomy that is too complex for immediate definitive cardiac repair. The decision to place a BT shunt is made by a multidisciplinary team including pediatric cardiologists, pediatric cardiac surgeons, cardiac intensivists, and neonatologists, typically within the first hours to days of life when prostaglandin E1 infusion to maintain the patent ductus arteriosus becomes insufficient.

Typical candidates include neonates weighing as little as 2 to 3 kilograms with oxygen saturations below 75% to 80% despite prostaglandin therapy. The procedure is indicated when the child cannot maintain adequate systemic oxygen saturation for end-organ perfusion. Infants with balanced circulations (adequate mixing and acceptable saturations) may be observed and managed medically until they reach a size and age more favorable for definitive repair, potentially avoiding the need for a shunt altogether.

Relative contraindications include the availability of a primary repair option (e.g., full repair of Tetralogy of Fallot in an adequately sized neonate), severe pulmonary artery hypoplasia where a shunt may cause excessive pulmonary blood flow to one lung, and severe associated non-cardiac anomalies or chromosomal conditions where the prognosis is limited regardless of cardiac intervention. In some cases, alternative palliative strategies such as a right ventricle-to-pulmonary artery (Sano) conduit or ductal stenting via catheter intervention may be preferred over a BT shunt based on the specific anatomy.

The modified Blalock-Taussig shunt (mBTS) is the current standard technique. The procedure is performed through a median sternotomy (midline chest incision) or lateral thoracotomy (side chest incision), depending on surgeon preference and whether concurrent cardiac procedures are needed. A PTFE (Gore-Tex) graft, typically 3.0 mm for neonates under 3 kg and 3.5 to 4.0 mm for larger infants, is anastomosed end-to-side from the innominate or right subclavian artery to the right pulmonary artery. The procedure can be performed on or off cardiopulmonary bypass.

The classic BT shunt, in which the subclavian artery is directly divided and anastomosed to the pulmonary artery, is rarely performed today. It has been supplanted by the modified technique due to concerns about subclavian artery sacrifice (compromising arm blood flow), unpredictable pulmonary blood flow, and distortion of pulmonary artery anatomy. However, the classic technique remains relevant in resource-limited settings where synthetic graft material may not be available.

Alternative palliative procedures include the Sano shunt (RV-PA conduit), which connects the right ventricle directly to the pulmonary artery using a valveless conduit. This approach is sometimes preferred in the Norwood procedure for HLHS, as it may provide more stable hemodynamics. Ductal stenting is an emerging catheter-based alternative to surgical shunting, where a stent is placed within the patent ductus arteriosus to maintain pulmonary blood flow without open surgery. This is increasingly used in select institutions, particularly for high-risk neonates who may not tolerate general surgery.

The central shunt, connecting the ascending aorta directly to the main pulmonary artery with a Gore-Tex graft, is another surgical alternative that provides balanced bilateral pulmonary blood flow but carries a higher risk of pulmonary artery distortion. Surgical planning involves detailed echocardiographic and sometimes CT/MRI assessment of the cardiac anatomy, pulmonary artery size, and arch anatomy to determine the optimal shunt strategy.

The primary and most critical benefit of the BT shunt is survival. Without surgical intervention, many cyanotic congenital heart defects are fatal within the first weeks to months of life. The BT shunt provides a reliable, controlled source of pulmonary blood flow that raises systemic oxygen saturations from critically low levels (often 50-70%) to acceptable ranges (typically 75-85%), enabling organ perfusion and allowing the infant to grow and thrive.

By serving as a bridge to definitive repair, the BT shunt allows the child's heart, lungs, and pulmonary vasculature to develop and grow, improving candidacy for subsequent corrective surgery. In single ventricle pathways, the BT shunt is the first stage in a planned series of surgeries (typically Norwood, Glenn, and Fontan) that ultimately establish a viable long-term circulation. The shunt also promotes pulmonary artery growth by providing forward flow, which is essential for the success of later surgical stages.

Operative survival for the modified BT shunt at experienced centers is 90% to 95%, with interstage mortality (between shunt placement and the next surgery) of 5% to 15% depending on the underlying diagnosis. Neurodevelopmental outcomes have improved with modern surgical techniques, perfusion strategies, and post-operative intensive care management. Long-term quality of life for survivors of staged congenital heart repair continues to improve, with many individuals leading active, productive lives into adulthood.

Shunt thrombosis (occlusion) is the most feared early complication, occurring in approximately 5% to 12% of cases. When the shunt clots, pulmonary blood flow ceases abruptly, causing acute cyanosis that constitutes a surgical emergency. Risk factors include small shunt size, low cardiac output, dehydration, and hematological abnormalities. Aspirin or heparin anticoagulation is typically administered post-operatively to reduce thrombosis risk, and many centers prescribe low-dose aspirin for the entire duration the shunt is in place.

Overcirculation (excessive pulmonary blood flow) can occur if the shunt provides more blood flow than needed, leading to pulmonary edema, heart failure, and hemodynamic instability. This is more common with larger shunt sizes relative to the patient's weight and is managed with diuretics and, in severe cases, shunt banding or revision. Conversely, shunt stenosis (narrowing over time) can lead to gradually decreasing pulmonary blood flow and progressive cyanosis, potentially requiring early advancement to the next surgical stage.

Pulmonary artery distortion at the shunt insertion site can complicate subsequent surgical repairs. This occurs in 10% to 20% of cases and may require pulmonary arterioplasty during the next operation. Phrenic nerve injury causing diaphragmatic paralysis occurs in 2% to 5% of cases and can prolong ventilator dependence. Chylothorax (lymphatic fluid leakage into the chest) affects 2% to 4% of patients. Infection of the prosthetic graft is rare (under 2%) but serious, potentially requiring shunt removal and replacement. Other risks include bleeding, recurrent laryngeal nerve injury (causing vocal cord paralysis), and the general risks of neonatal surgery and anesthesia.

Post-operative care for BT shunt patients occurs in the pediatric cardiac intensive care unit (PCICU), where the infant is closely monitored for oxygen saturation, hemodynamic stability, shunt patency (confirmed by continuous murmur auscultation), and end-organ perfusion. Mechanical ventilation is typically required for 1 to 3 days, and total ICU stays range from 5 to 14 days. Anticoagulation with heparin is initiated in the immediate post-operative period, transitioning to low-dose aspirin (3-5 mg/kg/day) before discharge.

After discharge, the infant requires close cardiology follow-up, typically every 2 to 4 weeks. Parents are educated on monitoring for signs of shunt malfunction, including increasing cyanosis, decreased feeding, excessive sleepiness, and rapid breathing. Pulse oximetry monitoring at home is often prescribed, with target saturations typically between 75% and 85% for single ventricle patients. Weight gain and growth are closely tracked, as adequate growth is essential before the next surgical stage.

The next surgical procedure — typically a bidirectional Glenn or hemi-Fontan for single ventricle patients, or complete intracardiac repair for Tetralogy of Fallot — is usually planned at 4 to 6 months of age when the child has grown sufficiently. Preoperative evaluation includes echocardiography and often cardiac catheterization to assess pulmonary artery pressures, pulmonary artery growth, and shunt patency. The BT shunt is ligated and divided at the time of the subsequent surgery. Long-term follow-up with a congenital heart disease specialist continues throughout childhood and into adulthood, including regular echocardiography, exercise testing, and assessment of neurodevelopmental milestones.

The cost of BT shunt surgery reflects the complexity of neonatal cardiac care, including the surgical procedure itself, extended ICU stays, specialized equipment, and multidisciplinary team involvement. In the United States, total hospitalization costs for a BT shunt procedure typically range from $80,000 to $200,000, encompassing surgery, PCICU stay, mechanical ventilation, medications, imaging, and post-operative monitoring. In the United Kingdom, the procedure is covered by the NHS at designated pediatric cardiac surgical centers.

Medical tourism destinations with established pediatric cardiac surgery programs, such as India, offer BT shunt procedures at significantly reduced costs — often $10,000 to $30,000 — while maintaining high surgical quality at accredited centers. However, families must consider the additional complexities of traveling internationally with a critically ill neonate, including the need for ongoing follow-up care, proximity to emergency cardiac services, and coordination with home country cardiologists for long-term management.

Key cost determinants include the length of ICU and hospital stay (which can extend to weeks in complicated cases), the need for additional procedures or reoperations, prosthetic graft material costs, and the intensity of post-operative monitoring. Most health insurance plans and national health systems cover BT shunt surgery as a medically necessary procedure for life-threatening congenital heart disease. Families should work closely with social workers and insurance coordinators at the treating hospital to navigate coverage, pre-authorization requirements, and any out-of-pocket expenses for travel and accommodation during the hospitalization period.

Ductal stenting is an increasingly utilized catheter-based alternative to surgical BT shunting. This minimally invasive approach involves advancing a catheter through the femoral or umbilical vessels to the patent ductus arteriosus and deploying a stent to maintain its patency. Ductal stenting avoids the need for thoracotomy or sternotomy, may result in shorter hospital stays, and provides bilateral pulmonary blood flow. Studies comparing ductal stenting to surgical shunting show comparable early outcomes, though long-term data are still maturing. This approach is not suitable for all anatomic variants.

Primary complete repair is the preferred approach when feasible, as it corrects the underlying cardiac defect in a single operation and avoids the need for a palliative shunt. For example, complete repair of Tetralogy of Fallot in the neonatal period is increasingly performed at experienced centers, with excellent outcomes in appropriately selected patients. This approach eliminates the risks associated with shunt surgery and the interstage period, though it requires adequate patient size and favorable anatomy.

Right ventricle-to-pulmonary artery (RV-PA or Sano) conduit is used as an alternative to the BT shunt in the Norwood procedure for hypoplastic left heart syndrome. The Sano shunt may provide more stable hemodynamics and higher diastolic blood pressure compared to the BT shunt, though it requires a right ventriculotomy. Institutional experience and surgeon preference often guide the choice between BT and Sano shunts. Pulmonary artery banding serves the opposite purpose — restricting pulmonary blood flow in cases of overcirculation — and is used for different congenital defects. Medical management with prostaglandin E1 infusion maintains ductal patency temporarily but is not a long-term solution due to apnea risk and the need for continuous intravenous access.